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General Information

New treatment for multiple
sclerosis could halt disease
progression without
weakening immune system.
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• Multiple Sclerosis (MS) is a
debilitating neurological
and autoimmune disease in
which immune cells cause
demyelination of axons in
nervous tissue.
• Current treatments for the
disease are principally
aimed at weakening the
immune system to therefore
weaken the autoimmune
attack on the brain. This
leaves patients prone to
other sicknesses.
• We seek a treatment that
prevents the immune cells
from entering the central
nervous system (CNS)
thereby protecting its cells.
• We can prevent immune
cells from entering the CNS
by strengthening the bloodbrain barrier through
targeting claudin-5 proteins
in the tight junctions.
• This new treatment could
mean increased health and
peace of mind for MS
patients undergoing
treatment.
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Additional
Information
• Dual Chimera claudin
proteins have been shown
to increase tight junction
(TJ) strength. We can use
this protein to prove our
ability to diminish
paracellular transport of
immune cells in vitro
using trans well inserts. In
our case we will start with
CD4+ T cells because they
have been found in active
MS lesions.
• We will then find a small
molecule that can more
efficiently strengthen
claudin 5 in the TJ. This
will also prevent poor side
effects from treatment.
• Effective molecules can
be tested for efficacy in
vivo using an animal
model called experimental
autoimmune encephalomyelitis.

